Evidence map›Paper›PMID 39969198›Full record

ArticleBlood advances2025

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells.

Sara E F Kost, Ali Saleh, Jennifer Brown, Shek H Yuan, Bozena Kuzio, Lin Yang, Versha Banerji, Spencer B Gibson, James B Johnston, Sachin Katyal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara E F KostPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.
Ali SalehPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.
Jennifer BrownPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.ORCID 0009-0008-8657-1053
Shek H YuanPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.
Bozena KuzioPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.
Lin YangDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Versha BanerjiPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.ORCID 0000-0002-7415-8818
Spencer B GibsonPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.ORCID 0000-0003-0119-732X
James B JohnstonPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.ORCID 0000-0001-6614-083X
Sachin KatyalPaul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada.ORCID 0000-0002-7790-4054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39969198
PMCPMC12142507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.